|Other Names||BTB/POZ domain-containing protein 2, BTBD2|
|Target/Specificity||The synthetic peptide sequence is selected from aa 270-281 of HUMAN BTBD2|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Cytoplasm, P-body. Note=Cytoplasmic bodies|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The C-terminus of the protein encoded by this gene binds topoisomerase I. The N-terminus contains a proline-rich region and a BTB/POZ domain (broad-complex, Tramtrack and bric a brac/Pox virus and Zinc finger), both of which are typically involved in protein-protein interactions. Subcellularly, the protein localizes to cytoplasmic bodies.
Olejnik-Schmidt, A.K., et al. Arch. Virol. 153(5):983-990(2008)
Stelzl, U., et al. Cell 122(6):957-968(2005)
Barrios-Rodiles, M., et al. Science 307(5715):1621-1625(2005)
Colland, F., et al. Genome Res. 14(7):1324-1332(2004)
Grimwood, J., et al. Nature 428(6982):529-535(2004)
Xu, L., et al. Exp. Cell Res. 288(1):84-93(2003)
Yamada, A., et al. Cancer Res. 63(11):2829-2835(2003)
Xu, L., et al. BMC Genomics 3 (1), 1 (2002) :
Carim-Todd, L., et al. Gene 262 (1-2), 275-281 (2001) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.